Black Diamond Therapeutics, Inc.
BDTX Healthcare Biotechnology
Black Diamond Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.0 million. In the quarter to June 2026, EPS grew 10.5% and free cash flow grew 12.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow BDTX
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
+8 more quarters Free account |
135.50 | 128.65 | 118.26 | 110.51 |
Other current assets |
3.49 | 3.79 | 4.71 | 4.89 | |
Total current assets |
138.99 | 132.44 | 122.97 | 115.39 | |
Property, Plant, Equpment (Net) |
1.13 | 0.37 | 0.34 | 0.31 | |
Long-Term Investments |
0.83 | 0.83 | 0.83 | 0.83 | |
Long-term assets (Other) |
0.12 | 0.07 | 0.03 | 0.29 | |
Total non-current assets |
18.74 | 10.57 | 9.96 | 9.64 | |
Total Assets |
157.73 | 143.01 | 132.92 | 125.03 | |
Accounts Payable |
0.98 | 0.58 | 2.97 | 1.40 | |
Accrued Expenses |
14.57 | 15.15 | 11.57 | 14.44 | |
Total current liabilities |
15.55 | 15.73 | 14.53 | 15.84 | |
Total non-current liabilities |
16.04 | 15.07 | 14.09 | 13.10 | |
Total liabilities |
31.58 | 30.80 | 28.62 | 28.94 | |
Additional Paid In Capital |
575.63 | 576.84 | 578.10 | 579.83 | |
Common Stock (Net) |
0.01 | 0.01 | 0.01 | 0.01 | |
Retained Earnings |
(449.62) | (464.74) | (473.78) | (483.68) | |
Common Equity (Total) |
126.15 | 112.21 | 104.30 | 96.09 | |
Shareholders Equity (Total) |
126.15 | 112.21 | 104.30 | 96.09 | |
Shareholders Equity and Liabilities (Total) |
157.73 | 143.01 | 132.92 | 125.03 | |
Shares (Common) |
56.94 | 57.14 | 57.30 | 57.45 | |
Shareholders Equity (Tangible) |
126.15 | 112.21 | 104.30 | 96.09 | |
Net Debt |
(135.50) | (128.65) | (118.26) | (110.51) |